Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Papillomavirus-like particles (VLPs) are a promising prophylactic vaccine candidate to prevent human papillomavirus (HPV) infections and associated epithelial neoplasia. However, they are unlikely to have therapeutic effects because the virion capsid proteins are not detected in the proliferating cells of the infected epithelia or in cervical carcinomas. To increase the number of viral antigen targets for cell-mediated immune responses in a VLP-based vaccine, we have generated stable chimeric VLPs consisting of the L1 major capsid protein plus the entire E7 (11 kDa) or E2 (43 kDa) nonstructural papillomavirus protein fused to the L2 minor capsid protein. The chimeric VLPs are indistinguishable from the parental VLPs in their morphology and in their ability to agglutinate erythrocytes and elicit high titers of neutralizing antibodies. Protection from tumor challenge was tested in C57BL/6 mice by using the tumor cell line TC-1, which expresses HPV16 E7, but not the virion structural proteins. Injection of HPV16 L1/L2-HPV16 E7 chimeric VLPs, but not HPV16 L1/L2 VLPs, protected the mice from tumor challenge, even in the absence of adjuvant. The chimeric VLPs also induced protection against tumor challenge in major histocompatibility class II-deficient mice, but not in beta2-microglobulin or perforin knockout mice implying that protection was mediated by class I-restricted cytotoxic lymphocytes. These findings raise the possibility that VLPs may generally be efficient vehicles for generating cell-mediated immune responses and that, specifically, chimeric VLPs containing papillomavirus nonstructural proteins may increase the therapeutic potential of VLP-based prophylactic vaccines in humans.
Greenstone
H L
HL
Laboratory of Cellular Oncology, National Institutes of Health, 36 Convent Drive, MSC 4040, Bethesda, MD 20892-4040, USA.
Nieland
J D
JD
de Visser
K E
KE
De Bruijn
M L
ML
Kirnbauer
R
R
Roden
R B
RB
Lowy
D R
DR
Kast
W M
WM
Schiller
J T
JT
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D016367:Baculoviridae; D002213:Capsid / Q000235:genetics; D036022:Capsid Proteins; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D002678:Chimera; D005814:Genes, Viral; D007111:Immunity, Cellular; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology*; D009500:Neutralization Tests; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D011233:Precipitin Tests; D011991:Receptors, Virus / Q000276:immunology; D018411:Spodoptera; D014614:Vaccines, Synthetic / Q000276:immunology*; D015678:Viral Structural Proteins / Q000235:genetics; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D036022:Capsid Proteins; C063316:L2 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011991:Receptors, Virus; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16